Valentina Bellani
Overview
Explore the profile of Valentina Bellani including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
45
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bellani V, Mora B, Iurlo A, Passamonti F
Leuk Lymphoma
. 2025 Feb;
:1-13.
PMID: 39960832
Calreticulin (CALR) is a chaperone protein that plays a crucial role in protein folding quality control and calcium homeostasis. Mutations in result in a mutated protein lacking key calcium-binding sites...
2.
Cattaneo D, Bucelli C, Bellani V, Mora B, Iurlo A
Hematol Oncol
. 2024 Sep;
42(5):e3309.
PMID: 39275966
The therapeutic armamentarium of chronic myeloid leukemia (CML) has dramatically improved after small molecule tyrosine kinase inhibitors (TKIs) targeting BCR::ABL1 became available, with a life expectancy now close to that...
3.
Mora B, Bucelli C, Cattaneo D, Bellani V, Versino F, Barbullushi K, et al.
Curr Hematol Malig Rep
. 2024 Aug;
19(5):223-235.
PMID: 39179882
Purpose Of Review: Myelofibrosis (MF) includes prefibrotic primary MF (pre-PMF), overt-PMF and secondary MF (SMF). Median overall survival (OS) of pre-PMF, overt-PMF and SMF patients is around 14 years, seven...
4.
Cattaneo D, Marchetti A, Bucelli C, Galli N, Lionetti M, Bellani V, et al.
Clin Exp Med
. 2024 Jul;
24(1):165.
PMID: 39042228
Here, we reviewed clinical-morphological data and investigated mutational profiles by NGS in a single-center series of 28 consecutive patients admitted to our hospital between September 2011 and November 2021 for...
5.
Cattaneo D, Galli N, Bucelli C, Fidanza C, Bellani V, Artuso S, et al.
Ann Hematol
. 2024 Jun;
103(8):2787-2795.
PMID: 38864904
We evaluated RDW in a single-center series of 61 consecutive patients with primary and secondary MF at diagnosis and during treatment with ruxolitinib (RUX) and examined any possible prognostic impact....
6.
Bellani V, Croci G, Bucelli C, Maronese C, Alberti S, Iurlo A, et al.
J Dermatol
. 2023 May;
50(10):1330-1334.
PMID: 37248740
Lymphomatoid papulosis (LyP) is a benign condition, listed among primary cutaneous CD30+ lymphoproliferative disorders. Its typical picture consists of relapsing-remitting papular lesions and it can be encountered in the course...
7.
Cattaneo D, Bucelli C, Marchetti A, Lionetti M, Fermo E, Bellani V, et al.
Ann Hematol
. 2023 Apr;
102(6):1409-1420.
PMID: 37079068
Here, we reviewed clinical-morphological data and investigated mutational profiles by NGS in a single-center series of 58 consecutive MPN-SVT patients admitted to our hospital between January 1979 and November 2021....
8.
Pasquale R, Bucelli C, Bellani V, Zappa M, Iurlo A, Cattaneo D
Front Oncol
. 2022 Sep;
12:1012268.
PMID: 36176390
The spectrum of TKI-related adverse events (AEs) is variable. Pleural effusion (PE) is a frequent AE attributable to dasatinib treatment, while it is only rarely associated with nilotinib. The pathogenetic...
9.
Fattizzo B, Pasquale R, Bellani V, Barcellini W, Kulasekararaj A
Front Immunol
. 2021 Dec;
12:791429.
PMID: 34899761
The complex pathophysiologic interplay between SARS-CoV-2 infection and complement activation is the subject of active investigation. It is clinically mirrored by the occurrence of exacerbations of complement mediated diseases during...
10.
Fattizzo B, Bellani V, Pasquale R, Giannotta J, Barcellini W
Front Oncol
. 2021 Oct;
11:748610.
PMID: 34660312
Large granular lymphocytes (LGL) are lymphoid cells characterized by either a T-cell or a natural killer phenotype whose expansion may be reactive to toxic, infectious, and neoplastic conditions, or result...